Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

March 31, 2011

Conditions
Anemia
Interventions
DRUG

Ferric Carboxymaltose

15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.

DRUG

Iron Dextran

As determined by the investigator to a maximum cumulative dose of 2,250 mg.

Trial Locations (1)

19403

Luitpold Pharmaceuticals, Norristown

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT00704028 - Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Iron Dextran in Treating Iron Deficiency Anemia | Biotech Hunter | Biotech Hunter